Compare CBLL & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBLL | ACHV |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.2M | 833.5M |
| IPO Year | 2024 | 2018 |
| Metric | CBLL | ACHV |
|---|---|---|
| Price | $24.74 | $8.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $23.20 | $14.67 |
| AVG Volume (30 Days) | 359.7K | ★ 1.3M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.93 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,063,000.00 | N/A |
| Revenue This Year | $29.57 | N/A |
| Revenue Next Year | $28.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.09 | N/A |
| 52 Week Low | $10.85 | $2.62 |
| 52 Week High | $25.33 | $8.61 |
| Indicator | CBLL | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 72.01 | 69.38 |
| Support Level | $22.97 | $3.99 |
| Resistance Level | $25.33 | $8.61 |
| Average True Range (ATR) | 0.78 | 0.40 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 75.00 | 90.41 |
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.